Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ribavirin

Criteria

Inclusion Criteria:

• Chronic hepatitis C of any genotype;

• Prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin did not result in a sustained virological response;

• Inclusion criteria listed on the approved label in each country;

• Willingness of the patient to participate and sign the Informed Consent Form.

Exclusion Criteria:

• Patient exclusion from this observational/non-interventional study will be determined by the treating physician and will be based on the local label in each country.